Patrick is the managing editor of PharmaBoardroom
In 2024, global biopharma faced a challenging landscape shaped by geopolitical tensions and cost containment measures in key markets. Despite these pressures, most major players perhaps surprisingly opted to retain…
François Bayrou’s new administration in France, sworn in after the previous, three-month-old government was toppled by a no-confidence vote, brings a new health minister to a post recently characterized by…
A summary of some of the latest news from China’s pharma industry, including AbbVie’s blood cancer licensing option with Simcere; Lonza’s China manufacturing expansion; Merck’s obesity deal with Hansoh Pharma;…
While the year’s tally of green lights from the FDA’s Center for Drug Evaluation and Research (CDER) is lower than the previous year’s, 2024 saw several long-awaited therapies reach the…
With a record number of recent approvals representing game-changing potential for conditions like sickle cell disease, a significant number of advanced therapies making progress in the clinic, and an uptick…
A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’…
Throughout the year PharmaBoardroom has talked to pharma and biotech executives and life sciences opinion leaders across the globe, gathering vital insights into local markets, learning about promising new therapies,…
A roundup of some of the top news coming out of the Central and Eastern European (CEE) region’s pharma industry, including Poland’s first draft of a national critical medicines list;…
Since raising USD 289 million in its Spring 2020 Hong Kong IPO, InnoCare Pharma has had a remarkable rise. Led by a team of Big Pharma veterans and now also…
US-headquartered global genomic sequencing giant Illumina has endured a tough few years. However, now that various legal wrangles over its acquisition of cancer diagnostics developer GRAIL have been largely resolved…
Eye health, despite being essential for most of us in our daily lives, receives significantly less research funding than fields like cancer or diabetes. According to IQVIA, global spending on…
Diabetes is a growing health concern in China and – given the country’s population size – a major contributor to global diabetes levels. Indeed, a recent study in The Lancet…
See our Cookie Privacy Policy Here
